# Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

> **NCT05282433** · PHASE2 · UNKNOWN · sponsor: **Zhongnan Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

## Interventions

- **DRUG:** Surufatinib

## Key facts

- **NCT ID:** NCT05282433
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-16
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282433, "Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05282433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*